Paul Tudor Jones’s Ovid Therapeutics OVID Stock Holding History

Paul Tudor Jones’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,677	Closed	-$32K	–	1786
2020 Q4	$32K	Buy	+13,677	New	+$63.8K	﹤0.01%	1294

Other funds holding OVID

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's OVID Position: Q1 2021 in Review

Paul Tudor Jones sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 13,677 shares — an estimated $32K sold.

Paul Tudor Jones first reported a position in OVID in Q4 2020 and held it in 1 quarter. The position peaked at $32K in Q4 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

Paul Tudor Jones reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
Paul Tudor Jones sold 13,677 Ovid Therapeutics shares in Q1 2021, an estimated $32K.
Paul Tudor Jones first reported a position in Ovid Therapeutics in Q4 2020 and held it in 1 quarter.
Paul Tudor Jones's Ovid Therapeutics position peaked at $32K in Q4 2020.
88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Tudor Investment Corp's 13F filing for Q1 2021, filed 17 May 2021.